查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1105804

猴痘治疗药的全球市场 - 产业规模，占有率，趋势，机会，预测:各治疗，各终端用户，各地区(2017年～2027年)

Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin ), By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球猴痘治疗药的市场规模，在2023年～2027年的预测期间内预计以大幅度的年复合成长率成长。

市场成长，可能起因于在欧美人们之间病毒感染疾病突然发生。

本报告提供全球猴痘治疗药市场相关调查分析，各市场区隔的预测，各地区的分析，竞争情形等资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 COVID-19对全球猴痘治疗药市场的影响

第5章 客户的迴响

  • 常见猴痘症状
  • 猴痘的盛行率:性别
  • 猴痘的盛行率:各年龄层
  • 猴痘的盛行率:各地区

第6章 全球猴痘治疗药市场预测

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各治疗(天花疫苗，抗病毒药物，牛痘免疫球蛋白(VIG))
    • 各终端用户(医院，专门诊疗所，门诊手术中心，其他)
    • 各企业(2021年)
    • 各地区
  • 产品市场地图

第7章 北美的猴痘治疗药市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 北美:各国分析
    • 美国的猴痘治疗药市场预测
    • 加拿大的猴痘治疗药市场预测

第8章 欧洲的猴痘治疗药市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 欧洲:各国分析
    • 英国的猴痘治疗药市场预测
    • 德国的猴痘治疗药市场预测
    • 法国的猴痘治疗药市场预测
    • 比利时的猴痘治疗药市场预测
    • 荷兰的猴痘治疗药市场预测
    • 瑞典的猴痘治疗药市场预测
    • 义大利的猴痘治疗药市场预测
    • 西班牙的猴痘治疗药市场预测

第9章 亚太地区的猴痘治疗药市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 亚太地区:各国分析
    • 澳洲的猴痘治疗药市场预测
    • 新加坡的猴痘治疗药市场预测

第10章 中东、非洲的猴痘治疗药市场预测

  • 市场规模与预测
  • 市场占有率与预测
  • 中东、非洲:各国分析
    • 奈及利亚的猴痘治疗药市场预测

第11章 市场动态

  • 促进因素
  • 课题

第12章 市场趋势与发展

第13章 竞争情形

  • 企业简介
    • Chimerix Inc.
    • SIGA Technologies, Inc.
    • Emergent BioSolutions Inc.
    • Bavarian Nordic A/S
    • Hetero Drugs Limited
    • Mylan N.V.
    • Piramal Enterprises Limited
    • Olon S.p.A.
    • Teva Pharmaceutical Industries Limited
    • CIDIC Company Limited

第14章 策略性推荐事项

简介目录
Product Code: 10581

Global monkeypox therapeutics market is projected to register growth at a significant CAGR during the forecast period, 2023-2027. The market growth can be attributed to the sudden outburst of the viral infection among the population across Europe and United States. In the year 2003, monkeypox caused a commotion because it spread quickly, and the number of affected patients exceeded 40 in a matter of weeks. Although the disease spread was relatively well-controlled, the recent outbreak of infection and rapidly increasing cases pose a threat for another possible pandemic. Hence, the demand for effective treatment, vaccination, and other rare disease therapeutics are expected to support the growth of the global monkeypox therapeutics market over the next five years.

There is currently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and an increase in demand for pain and itch relief due to boils and rashes are positively influencing the growth of the global monkeypox therapeutics market.

Monkeypox is a viral infection that spreads like a highly communicable disease through mere touch and use of infected patient's material. The virus is related to smallpox, and the vaccination and drugs used to control smallpox are also somewhat effective against monkeypox diseases. Although no specific vaccine or treatment drug has yet been commercialised, research is still ongoing. Patients with compromised immunity, those suffering from chronic disease, certain skin conditions such as eczema, those recovering from a recent pandemic, and those suffering from other anti-viral infections are all at high risk of contracting the monkeypox.

Growing demand for timely vaccines and potential disease treatments may support the growth of the global monkeypox therapeutics market in the next five years. Governments are actively investing in the research and development of effective vaccines and drugs to control disease spread and treat affected patients. In addition, the government is taking steps to promote drug development using genetic engineering tools in order to provide vaccination in the event that the virus evolves and affects a larger portion of the population.

Genomic sequencing for the virus would elucidate the specific infection-causing sequences, which could aid in the early diagnosis of the viral infection and the development of effective vaccines for the population at risk of infection in the coming years. Furthermore, rising healthcare expenditures by the population is fuelling growing investments for the developmen to new vaccines, which is likely to aid the global monkeypox therapeutics market in the next five years.

The global monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is divided into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). The smallpox vaccine segment is anticipated to hold the largest share in the global monkeypox therapeutics market due to the rising number of cases of monkeypox.

Key players operating in the global monkeypox therapeutics market are Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited, among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

  • To analyze the historical growth in the market size of the global monkeypox therapeutics from 2017 to 2021.
  • To estimate and forecast the market size of global monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
  • To classify and forecast the global monkeypox therapeutics market based on treatment, end user, region, and company.
  • To identify the dominant region or segment in the global monkeypox therapeutics market.
  • To identify drivers and challenges for the global monkeypox therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global monkeypox therapeutics market.
  • To identify and analyze the profiles of leading players operating in the global monkeypox therapeutics market.
  • To identify key sustainable strategies adopted by market players in global monkeypox therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of the Global monkeypox therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums, and alliances

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Monkeypox Therapeutics Market, By Treatment:

Smallpox Vaccine

Antivirals

Vaccinia Immune Globulin (VIG)

  • Monkeypox Therapeutics Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

  • Monkeypox Therapeutics Market, By Region:

North America

  • United States
  • Canada

Asia-Pacific

  • Australia
  • Singapore

Europe

  • France
  • Germany
  • United Kingdom
  • Belgium
  • Netherlands
  • Sweden
  • Italy
  • Spain

Middle East & Africa

  • Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Monkeypox Therapeutics Market

5. Voice of Customer

  • 5.1. Commonly Observed Symptoms of Monkeypox
  • 5.2. Monkeypox Prevalence, By Gender
  • 5.3. Monkeypox Prevalence, By Age Group
  • 5.4. Monkeypox Prevalence, By Region

6. Global Monkeypox Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
    • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Company (2021)
    • 6.2.4. By Region
  • 6.3. Product Market Map

7. North America Monkeypox Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Monkeypox Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. Canada Monkeypox Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User

8. Europe Monkeypox Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. United Kingdom Monkeypox Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. Germany Monkeypox Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. France Monkeypox Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. Belgium Monkeypox Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Netherlands Monkeypox Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User
    • 8.3.6. Sweden Monkeypox Therapeutics Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Treatment
        • 8.3.6.2.2. By End User
    • 8.3.7. Italy Monkeypox Therapeutics Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Treatment
        • 8.3.7.2.2. By End User
    • 8.3.8. Spain Monkeypox Therapeutics Market Outlook
      • 8.3.8.1. Market Size & Forecast
        • 8.3.8.1.1. By Value
      • 8.3.8.2. Market Share & Forecast
        • 8.3.8.2.1. By Treatment
        • 8.3.8.2.2. By End User

9. Asia-Pacific Monkeypox Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. Australia Monkeypox Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. Singapore Monkeypox Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User

10. Middle East and Africa Monkeypox Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. Nigeria Monkeypox Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Company Profiles
    • 13.1.1. Company Details
    • 13.1.2. Financials (As reported)
    • 13.1.3. Key Market Focus and Geographical Presence
    • 13.1.4. Pricing of Target Products
    • 13.1.5. Market positioning
  • 13.2. Chimerix Inc.
  • 13.3. SIGA Technologies, Inc.
  • 13.4. Emergent BioSolutions Inc.
  • 13.5. Bavarian Nordic A/S
  • 13.6. Hetero Drugs Limited
  • 13.7. Mylan N.V.
  • 13.8. Piramal Enterprises Limited
  • 13.9. Olon S.p.A.
  • 13.10. Teva Pharmaceutical Industries Limited
  • 13.11. CIDIC Company Limited

14. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)